Key Highlights
- IDEAYA Biosciences announced successful Phase 2/3 trial outcomes for darovasertib plus crizotinib in metastatic uveal melanoma patients
- The combination therapy achieved median progression-free survival of 6.9 months compared to 3.1 months with standard care
- Disease progression risk decreased by 58% among patients receiving the combination treatment
- The overall response rate reached 37.1% for the combination therapy compared to 5.8% for standard treatment, including 5 complete responses versus none in the control group
- The company intends to submit a New Drug Application (NDA) to the FDA during the latter half of 2026
IDEAYA Biosciences (IDYA) shares experienced significant gains during Monday’s premarket session following the company’s announcement of successful Phase 2/3 clinical trial data for a dual-drug approach treating metastatic uveal melanoma, an uncommon and challenging eye cancer variant.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated darovasertib when used together with crizotinib. The findings demonstrated that the combination therapy more than doubled median progression-free survival when compared against current standard treatment protocols.
Participants receiving the combination therapy achieved a median PFS of 6.9 months. Meanwhile, those on standard treatment reached only 3.1 months. This outcome successfully met the study’s primary endpoint.
The combination therapy also reduced disease progression risk by 58%, a figure likely to capture significant attention from oncology-focused investors.
Impressive Secondary Outcome Measurements
The secondary outcomes proved equally compelling. The overall response rate for the darovasertib combination reached 37.1%, while standard care produced only 5.8%.
Five participants receiving the combination treatment achieved complete responses. The standard-care group recorded none whatsoever.
Median duration of response for the combination therapy measured 6.8 months. Researchers characterized the drug as well-tolerated, featuring a manageable safety profile.
Early trends also suggested potential overall survival advantages for the combination compared to standard treatment, although complete data for this measure remains immature.
Metastatic uveal melanoma has traditionally offered patients extremely limited effective therapeutic options. These trial outcomes position darovasertib as a potentially first-in-class therapy for this condition.
Regulatory Submission Targeted for Second Half 2026
IDEAYA announced plans to file a New Drug Application with the FDA during the second half of 2026, leveraging these clinical trial results.
This schedule positions a potential approval determination sometime during 2027, subject to FDA review timelines.
IDYA stock climbed as much as 26.36% during premarket trading, touching $38.60, according to Benzinga Pro data. Earlier tracking indicated gains around 15%, with shares trading near $35.
The stock had already been approaching its 52-week peak of $41.02 prior to Monday’s news. Throughout the past 12 months, IDYA has gained approximately 78%.
The overall market showed weakness on Monday, with S&P 500 futures declining roughly 0.6% during the timeframe of the premarket movement.
IDEAYA plans to share comprehensive trial data at an upcoming medical conference, with additional details anticipated later during 2026.
